Group 1 - The core viewpoint of the news is that拓新药业 experienced a decline in stock price and significant changes in financing activities on October 9, with a net financing outflow of 374.02 million yuan [1] - On October 9, the stock price of拓新药业 fell by 1.02%, with a trading volume of 73.72 million yuan [1] - As of October 9, the total balance of margin trading for拓新药业 was 155 million yuan, which accounts for 3.93% of its market capitalization [1] Group 2 - As of September 19, the number of shareholders of拓新药业 was 16,500, a decrease of 26.77% from the previous period [2] - The average number of circulating shares per shareholder increased by 36.55% to 5,527 shares [2] - For the first half of 2025,拓新药业 reported a revenue of 182 million yuan, a year-on-year decrease of 16.85%, and a net profit attributable to shareholders of -18.28 million yuan, a decrease of 927.39% [2] Group 3 - The main business of拓新药业 includes the research, production, and sales of chemical synthesis, biological fermentation nucleoside (acid) raw materials, and pharmaceutical intermediates [1] - The revenue composition of拓新药业 is 62.74% from pharmaceutical intermediates, 37.03% from raw materials, and 0.23% from other sources [1] - Since its A-share listing,拓新药业 has distributed a total of 94.64 million yuan in dividends, with 82.04 million yuan distributed over the past three years [2]
拓新药业10月9日获融资买入820.85万元，融资余额1.55亿元